Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
In clinical trials, Zepbound has demonstrated its ability to help patients shed, on average, 15 to 20 percent of their body weight over a year, a figure markedly greater than that achievable by diet and exercise alone
Our Leadership Sue Hudson Owner, IV Nutrition Ankeny Sue Hudson is a proud wife, mom of three, entrepreneur, motivational speaker, passionate community advocate, and the proud owner of IV Nutrition Ankeny
The 6-day half-life is the technical reason for once-weekly dosing
(2024, December 19)
If you're not getting enough L-carnitine through your diet, consider supplementing with NOW L-Carnitine